The efficacy data could help cushion Ibrance's losses of market share to Kisqali, a similar drug from Novartis.

Among patients with ER-positive/HER2-negative advanced breast cancer, treatment with camizestrant in combination with Kisqali ...

Experts discussed what other information is needed to understand how best to use Kisqali in treating patients in the adjuvant ...

While under competitive pressure from Novartis and Eli Lilly, Pfizer can tally up a unique trial win for its Ibrance in a ...

Reduction in distant recurrence consistently deepened beyond 3-year Kisqali treatment duration in patients with node-positive (N+) and high-risk node-negative (N0) disease, as well as between ...

Pfizer, facing increasing pressure from Novartis, is touting a Phase III win for Ibrance as the first clinical evidence supporting the CDK4/6 inhibitor class’ use in patients with a specific type of ...

It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...

Novartis (NVS) announced results from an updated analysis of the pivotal Phase 3 NATALEE trial of Kisqali that it says “underscore the extended ...

Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reported at the ASCO congress.

a population that represents 10% of breast cancer patients. Although not a game-changer for Pfizer, the data could could help ...